The Human Brain Project (HBP) said Executive Director and Head of the Project Coordination Office Chris Ebell has resigned "following a change of university leadership and differences of opinion on governance and on strategic orientations...

Axovant Sciences Ltd. (NASDAQ:AXON) hired Gavin Corcoran as EVP of R&D and appointed Michael Hayden as senior scientific advisor and chairman of the neurology company’s new scientific advisory board as part of an ongoing restructuring....

Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30. He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug also said CFO...

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...

Catalent Inc. (NYSE:CTLT) and Ascendis Pharma A/S (NASDAQ:ASND) each priced follow-on offerings, raising more than $380 million. Ascendis raised $134.9 million on Sept. 27 through the sale of 3.8 million ADSs at $35.50 in a...

Ascendis Pharma A/S (NASDAQ:ASND) and Catalent Inc. (NYSE:CTLT) each priced follow-on offerings, raising more than $380 million. Ascendis raised $134.9 million on Wednesday through the sale of 3.8 million ADSs at $35.50 in a follow-on...

Versartis Inc. (NASDAQ:VSAR) lost $18.93 (88%) to $2.67 on Friday after announcing after market close Thursday that somavaratan (VRS-317) missed the primary endpoint in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency...

Versartis Inc. (NASDAQ:VSAR) said somavaratan (VRS-317) missed the primary endpoint of non-inferiority to Genotropin somatropin in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency (GHD). In the intent-to-treat (ITT) population, twice-monthly subcutaneous...